AAIC 2020 | The role of phosphorylated tau in clinical trials

Elisabeth Thijssen, MSc, UCSF Memory and Aging Center, San Francisco, CA, and Amsterdam UMC, Amsterdam, The Netherlands, suggests how phosphorylated tau can be used as a prescreening agent before patients are chosen to partake in clinical trials. Further, phosphorylated tau levels can be measured throughout the trial as it could be a predictive marker and thus reflect target engagement. Thijssen concludes about how, in the future, phosphorylated tau measurements could be a primary marker taken by both GP and memory clinics as a tool for diagnosis. This interview was recorded during an online conference call with The Video Journal of Dementia (VJDementia).